Described is the evaluation in Brazil of the immune response of early immunization with trivalent oral poliovirus vaccine (TOPV). A total of 85 normal neonates from Sao Paulo were assigned one of the following immunization schedules: group A -one dose of TOPV at birth and subsequent doses at 2, 4, and 9 months of age; or group B -one dose of TOPV at 2, 4 and 6 months of age. Blood samples were collected sequentially from the mother at delivery, from the umbilical cord, and from the child at 2, 4, 6, 9 and 12 months of age for assay of poliovirus neutralizing antibodies. Administration of TOPV at birth, in addition to establishing immunity against poliomyelitis at an earlier stage, produced a superior immune response to poliovirus type 3. At the end of the first year, the proportion of susceptible individuals was 3.7% in group A and 25.9% in group B. When immunization against poliomyelitis is started at birth, excellent seroconversion rates are obtained from the third dose onward.
Introduction
Immunization of neonates with oral poliovirus vaccine (OPV) was studied extensively in the 1950s and 1960s (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recently, this possibility has been reevaluated, because in developing countries, where poliomyelitis is not yet under control, early vaccination would permit immunization at a time when there is little interference from intestinal organisms and ensure the administration of at least one dose while the child is still under medical care. In Sao Paulo, Brazil, more than 90% of deliveries occur in hospitals. Also, the occurrence in very young childrena of poliomyelitis that is associated with an immunity gap (11) would be prevented by earlier establishment of immunity against the disease. Recently, studies carried out in China (12) and in India (13) have reported excellent rates of seroconversion after early administration of poliovirus vaccine, with higher antibody titres during the first months of life (12, 14) .
On the basis of these data WHO now recommends a supplementary dose of polio vaccine at birth, in addition to the three doses for primary immunization (15, 16) . We therefore carried out a study to assess the immunological response to early poliomyelitis vaccination of neonates in Sao Paulo. 
Materials and methods

Study population
A total of 85 children from Sao Paulo were evaluated from March 1986 to September 1988. The children satisfied the following criteria: they were normal full-term newborn infants, had a birth weight of over 2500g, and a 5-minutes Apgar score of >7. In addition, their mothers had normal pregnancies, without infectious episodes, and amniorrhexis less than 12 hours before delivery. After obtaining the written consent of one of the parents, the neonates were assigned at random to one of two groups (A and B), each of which received different poliomyelitis immunization schedules. All children were followed up in the nursery and afterwards at monthly visits throughout the first year of life. Those who received an extra dose of vaccine as a result of immunization campaigns were excluded from the study. Of the 85 neonates at the beginning of the study, only 54 (27 in each group) followed the protocol until the end.
of Health, was used for both study groups; however, because the composition of the vaccine was modified during the study period, group B children received a higher concentration of vaccine to poliovirus type 3. The schedules and composition of vaccine used with the two study groups are shown below. -Group A: TOPV was given at birth ( Evaluation parameters Individuals whose poliovirus neutralizing antibody titres were .1:5 were considered to be seropositive (11, 18, 19 Sequential determination of poliovirus antibodies in a given child throughout the first year of life permits evaluation of the serological response to the vaccine. The results obtained were analysed for antibody level, seropositivity, susceptibility and seroconversion.
Antibody level
For group A children (who received TOPV at birth) a slight decrease in the antibody titres to P1 and P3 occurred between birth and the second month of life, but increased thereafter (Fig. 1) . In general there was a good serological response to this vaccination schedule, leading at the end of the first year to high antibody titres against the three polioviruses.
For group B children (who were immunized first at the age of 2 months) the antibody levels for the three polioviruses decreased significantly until the second month. This was due to the natural loss of maternal antibodies present at birth. The reduction in antibodies to P3 was more pronounced, with the increase in titres occurring only from the fourth month onward. At the end of the first year the mean titres for P2 (557.22) and P1 (153.03) were considerably greater than the mean for P3 (40.02).
Seropositivity
In group A the percentage seropositivity (titre >1:5) for P1 and P2 was rather high and constant during the first year of life. The seropositivity for P3 decreased in the second month, but recovered subsequently, and by the end of the primary immunization schedule, the protection rates against the three polioviruses were excellent (Fig. 2) (Pi=100%, P2=100%, and P3=96.3%).
In group B, although the seropositivity for P, and P2 remained high, there was a significant decrease in that for P3 until the fourth month (minimum seropositivity, 51.9%). At Early immunization of neonates with oral poliovirus vaccine 25 .9% (Fig. 3) .
Seroconversion
Seroconversion, an important parameter in evaluating the active response to a vaccine, was determined by assaying the antibody levels in both groups two months after each dose of vaccine had been administered (Fig. 4) . For children in group A, seroconversion increased progressively with each successive dose. After three doses (including dose zero given at birth, the rate of seroconversion for the three polioviruses was high (PI = 92.6%, P2 = 96.3%, P3 = 92.6%), and close to that obtained after four doses (dose 3) (P1 = 100%, P2 = 100%, P3 = 96.3%).
High rates of seroconversion for P1 (96.3%) and P2 (100%) were obtained for children in group B; however, only 74.1% of these children had seroconverted to the P3 vaccine virus by the end of the schedule.
Discussion
One of the problems associated with early immunization with TOPV is the possible interference of maternal antibodies with the response to the administered vaccine (1) (2) (3) (4) (5) (6) 12) . In the present study, passively transferred maternal antibodies were present in all but one neonate and did not seem to have influenced the final outcome, since almost all children in group A seroconverted. Dong et al. have shown that the seroconversion is delayed when high levels of maternal antibodies are present at birth (12) ; in contrast, we found this outcome only for P1. Because of the small number of patients in our study, the evaluation for other poliovirus types was difficult. The high gastric acidity during the first 24 hours of life (21, 22) and the presence of ingested amniotic fluid (23) could theoretically interfere with vaccines given immediately after birth; the children were therefore vaccinated on their second day of life. Also, the children in our study were routinely breast-fed.
Administration of a supplementary dose of TOPV at birth led to a higher level of polio antibodies during the first months of life (Fig. 1) , with a greater seropositivity (Fig. 2) , and consequently to a decrease in the proportion of susceptible individuals over this period (Fig. 3) . Use of a supplementary dose at birth led also to increased protection at the end of the primary immunization schedule: only Age (months) In India, John obtained excellent rates of seroconversion in children who received their first dose of poliovirus vaccine during the first week of life, the rates being slightly higher than those resulting from administration of the vaccine at 5 or 6 weeks of age (13) . In Brazil, Neves et al. have reported better rates of seroconversion when administration of TOPV is started in the first rather than in the third month of life (24) . It should be noted that these two studies were performed in tropical countries, where the efficacy of the routinely administered oral poliovaccine is lower than that in countries with temperate climates (25, 26) . Several factors play a role in accounting for these differences: potency is reduced in tropical countries because of deficiencies in the storage of the vaccine (27) ; there could be differences in inhibitory factors in the digestive tract that have an effect on the implantation and replication of the vaccine virus (28) ; and the interference by other enteroviruses in small children in tropical countries may reduce the immune response (29) (30) (31) (32) . The incidence of enterovirus infections among neonates in Brazil (33) and elsewhere (34) is significantly lower than that among older children, and may account for the better seroconversion rates observed in younger children. Our results indicate that there is an improved serological response to TOPV when the schedule is started early, during the neonatal period, particularly as far as poliovirus type 3 is concerned.
During the outbreak of poliomyelitis in northeast Brazil in 1986, most cases were due to poliovirus type 3. Epidemiological investigations have revealed that the TOPV used to immunize the children has a low efficacy, particularly in terms of the P3 component. Higher seroconversion rates were obtained by doubling the P3 level (35) , and this led the Brazilian Ministry of Health to modify the composition of the vaccine used, increasing the P3 level from 300 000 TCID50 per dose to 500 000 TCID50 per dose.
The children in group B in our study who received their first dose of TOPV in their second month of life, were immunized from the beginning with a vaccine that had the higher P3 level. Even so, the rate of seroconversion to P3 was lower than that of children who received their first dose at birth using vaccine with a P3 level of 300 000 TCID50 per dose. This indicates that immunization of neonates with TOPV may be a much more relevant factor than use of a higher vaccine concentration.
With the official schedule, beginning in the second month of life, primary immunization with three doses of TOPV resulted in about 25% of the children remaining incompletely immunized, and susceptible to poliovirus type 3. In the case of exposure to wild poliovirus this proportion of the population can be considered to be at risk. In contrast, with early immunization, better protection can be achieved and the risk may diminish considerably.
When a supplementary dose of TOPV is given at birth (zero dose), excellent rates of seroconversion for the three poliovirus types are produced from the third dose onward, and after the fourth dose, the seroconversion rates are still slightly higher (Fig. 4) .
No difficulty was experienced in administering the TOPV to neonates. The schedule is feasible operationally and requires no specialized technical knowledge or additional equipment. In view of the results obtained, we propose that immunization against poliomyelitis be initiated early in the neonatal period; every newborn can receive the first dose of polio vaccine before being discharged from hospital. This measure together with other efforts to improve vaccination will contribute considerably to the control of poliomyelitis. 
